Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Last updated: May 9, 2025
Sponsor: Memorial Sloan Kettering Cancer Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Abdominal Cancer

Digestive System Neoplasms

Carcinoid Syndrome And Carcinoid Tumours

Treatment

positron emission tomography (PET) scans

Clinical Study ID

NCT06448208
24-100
  • Ages > 18
  • All Genders

Study Summary

People with neuroendocrine cancer typically have imaging scans before and after treatment, including positron emission tomography (PET) scans. The scans are analyzed using a set of criteria that describes how the disease has responded to treatment. The purpose of this study is to establish new criteria for doctors to use when evaluating these PET scans. Researchers are testing whether these new criteria are useful for predicting whether a person's cancer gets better, gets worse, or stays the same. Researchers will also compare these new criteria to the current standard criteria for evaluating imaging scans.

Eligibility Criteria

Inclusion

Subjects affected by histologically proven, somatostatin-receptor positive, metastatic or inoperable well-differentiated G1, G2 or G3 neuroendocrine tumors (NETs) candidate to receive PRRT with 177Lu-DOTATATE per standard of care.

Inclusion Criteria:

  1. Histologically proven or cytologically confirmed, metastatic or inoperable NETs

  2. Measurable disease as defined by RECIST 1.1.

  3. Overexpression of somatostatin receptors of the target lesions at somatostatinreceptor imaging (68Ga-DOTATATE or 64Cu-DOTATATE PET/CT) with SUV of lesions greaterthan normal liver at least in 1 metastasis.

Exclusion

Exclusion Criteria:

  1. Neuroendocrine Carcinoma), small and large cell type; MIxedNeuroendocrine-Nonneuroendocrine Neoplasm (MiNEN).

  2. Presence of somatostatin receptor negative lesions.

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: positron emission tomography (PET) scans
Phase:
Study Start date:
June 03, 2024
Estimated Completion Date:
June 30, 2026

Connect with a study center

  • Memorial Sloan Kettering Cancer Center

    New York, New York 10065
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.